Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840185 | 0.86 | THRB (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3842803 | 0.84 | LMNA (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3842592 | 0.83 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3837840 | 0.74 | HTR7 (0.44) | CYP2D6HTR6POLBKDM4EALDH1A1 | |
| SCHEMBL3837780 | 0.73 | SIGMAR1 (0.38) | LMNABLMCYP2D6HTR6CYP2C9 | |
| SCHEMBL3837835 | 0.70 | HTR2C (0.41) | LMNABLMCYP2D6HTR6CYP2C9 | |
| Hydrochloric Acid SCHEMBL4513858 | 0.69 | HTR2C (0.41) | LMNABLMCYP2D6HTR6CYP2C9 | |
| SCHEMBL3841744 | 0.69 | HPGD (0.38) | LMNABLMCYP2D6HTR6CYP2C9 | |
| SCHEMBL3867805 | 0.68 | CA12 (0.37) | LMNATHRBHTR6POLBKDM4E | |
| SCHEMBL3841799 | 0.68 | SLC6A1 (0.37) | LMNABLMCYP2D6HTR6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931341-B1 | 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS | SERVIER LAB (FR) | 2009-11-04 | — | — | EP | claimed |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | LES LABORATOIRES SERVIER (FR) | 2009-10-15 | — | — | US | claimed |
| EP-1931341-A2 | NOVEL 1H-INDOLE-PYRIDINECARBOXAMIDE DERIVATIVES AND 1H-INDOLE-PIPERIDINECARBOXAMIDE AND THEIR USE AS HYDROXALASE TYROSINE INDUCERS | Les Laboratoires Servier (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007006922-A2 | NOVEL 1H-INDOLE-PYRIDINECARBOXAMIDE DERIVATIVES AND 1H-INDOLE-PIPERIDINECARBOXAMIDE AND THEIR USE AS HYDROXYLASE TYROSINE INDUCERS | LES LABORATOIRES SERVIER (FR) | 2007-01-18 | — | — | WO | claimed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
| EP-1931341-B1 | 1H-INDOLE-PYRIDINECARBOXAMIDE AND 1H-INDOLE-PIPERIDINECARBOXAMIDE DERIVATIVES AND THEIR USE AS TYROSINE HYDROXYLASE INDUCERS | SERVIER LAB (FR) | 2009-11-04 | — | — | EP | disclosed |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | LES LABORATOIRES SERVIER (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2101768-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | Les Laboratoires Servier (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008099083-A2 | USE OF NEUROPROTECTIVE COMPOUNDS FOR OBTAINING DRUGS FOR TREATING NEURODEGENERATIVE DISEASES | LES LABORATOIRES SERVIER (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | NLN, GAP43, SNCA | CHRM2 977/4885CHRM4 1178/4885CHRM5 1150/4885 |
| US-20090258883-A1 | 1H-Indole-Pyridinecarboxamide and 1H-Indole-Piperidinecarboxamide Compounds | IDO1, AHR, IDO2 | CHRM2 314/4885CHRM4 900/4885CHRM5 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.